4041 Forest Park Avenue
About C2N DiagnosticsC2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration.
We formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). We reside at the Center for Emerging Technologies in St. Louis.
Founders: David Holtzman, Randall Bateman and Joel B. Braunstein
Founder and CEO: Joel B. Braunstein
Please click here for C2N Diagnostics job opportunities.
18 articles with C2N Diagnostics
C2N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight
C2N Diagnostics, LLC, a leader in advanced brain health diagnostics, announced it has received a $15 million program-related investment from GHR Foundation.
C2N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkers in the Diagnosis of Alzheimer’s Disease
C2N Diagnostics, LLC (“C2N”) provided today a recap of the multiple presentations at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, November 29 – December 2, 2022, in San Francisco, highlighting the clinical utility and performance of the company’s blood-based biomarkers for the evaluation of patients with cognitive impairment.
International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference
C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD® blood test, p-tau MAA™ and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer’s disease at the Clinical Trials on Alzheimer's Disease conference.
C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health
C2N Diagnostics announced it has entered a partnership with Grupo Fleury, one of Brazil’s leading healthcare companies, to bring blood-based tests that aid in early Alzheimer’s diagnosis to patient care in Brazil.
C2N’s New Blood Test Combining p-tau217 Ratio with Aβ42/40 Ratio Points to Accuracy Levels Comparable to Existing Standards of Care for Amyloid Diagnosis in the Evaluation of Patients with Cognitive Impairment
Data released from C2N Diagnostics, presented at the Alzheimer's Association International Conference, demonstrated that a blood test combining the Aβ42/40 ratio, a component of C2N’s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive cerebrospinal fluid tests in identifying Alzheimer’s brain pathology.
C2N Achieves ISO 13485:2016 Certification; Latest Development for Leader in Brain Health Sector
C2N Diagnostics has earned ISO 13485:2016 Certification for its quality management system.
C2N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices
C2N Diagnostics continues to build on its mission to provide exceptional laboratory services and products in the field of brain health.
C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C₂N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease.
PrecivityAD™ Blood Test’s Reach Expands to Europe and California Following Initial Launch; Test Detects Alzheimer’s Disease Pathology
Building on the first stage of its successful launch in the United States, C 2 N Diagnostics announces that the PrecivityAD™ blood test has achieved the CE Mark from the European Union (EU) as well as approval for its lab to conduct tests for California patients. This means the PrecivityAD™ test, a unique mass spectrometry-based blood test for detection of Alzheimer’s disease pathology, has met the quality stand
Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test
Alzheimer’s Breakthrough: C 2 N First to Offer a Widely Accessible Blood Test PrecivityAD TM Blood Test Answers Calls from Patients, Advocates, and Physicians Who Want Earlier Answers
C2N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
C 2 N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
C2N Diagnostics Reports High Accuracy of APTUS™-Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology
Dr. Tim West, Ph.D. Presented the Study Results at the 12th Annual Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego, CA
C2N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathology
C2N Diagnostics today announced that it will present data from a proof-of-concept study of its APTUS™-Aβ blood test on Friday December 6th at 5 PM at the Late Breaking session of Clinical Trials in Alzheimer’s Disease 2019 conference (Hilton Bayfront in San Diego, CA)
C2N Diagnostics Receives Breakthrough Device Designation from U.S. FDA for Blood Test to Screen for Alzheimer’s Disease Risk
FDA has granted Breakthrough Device Designation to C2N’s proprietary blood test for the initial screening of amyloid pathology in the brain associated with Alzheimer’s Disease C2N is conducting the PARIS Study, a two-phase pivotal clinical trial evaluating the clinical diagnostic performance of its test in individuals at high risk for Alzheimer’s Disease
C2N Reports Phase I Study Results Of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – In Subjects With Progressive Supranuclear Palsy
C2N Completes Phase I Clinical Study Of C2N-8E12 (ABBV-8E12) Among Individuals With Progressive Supranuclear Palsy
C2N And AbbVie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy